PRODUCTS
Oncofibro offers precision-engineered solutions designed to support advanced cell and gene therapy development, as well as animal health research.
Krysaygio™
- Krysaygio™ is an autologous T cell therapy that temporarily delivers MYC protein to exhausted or anergic T cells, reviving their metabolism, cytokine production, and cytotoxic activity without genetic modification or external IL-2.
- The therapy is prepared ex vivo and administered intravenously, enhancing T cell function before reinfusion to improve immune responsiveness in advanced solid tumors. Krysaygio™ has shown a favorable preliminary safety profile in early clinical studies. The first dose is administered intravenously under the supervision of an oncology nurse, with a short observation period afterward.
- Krysaygio™ has completed Phase 1/2 trials in Israel for solid tumors resistant to standard therapies, demonstrating safety and feasibility, and has an active IND in the US supporting ongoing Phase 1 studies in advanced melanoma. In Japan, it has received conditional approval as a low-risk (Class III) autologous ex vivo regenerative medicine therapy under the MHLW, administered at AER Clinic, Sendai, through a licensed cell processing center. The therapy is offered under a self-paying scheme with defined inclusion and exclusion criteria for advanced solid tumors, in accordance with the Act on the Safety of Regenerative Medicine (ASRM, updated 2024).
- Preclinical HSC applications: Building on the Krysaigio™ platform, Tat-MYC is also being explored in preclinical studies to support hematopoietic stem cell (HSC) survival, engraftment, and immune reconstitution. This work spans cord blood, G- CSF–mobilized peripheral blood, and bone marrow sources, with the goal of expanding Krysaigio™’s utility beyond T cells to stem cell therapies in the future.
Medical Concierge for Aer Clinic
-
Preliminary/Pre-requisite info Please provide: Blood test / Total Blood Count Diagnostic tests and any NGS/Pcr tests/Genetic tests CT/MRI Scans Pathology report Past/Current treatment Current oncologist
-
Screening Oncofibro clinician scientist will explain how Krysaygio™ works and address any questions and if patient is eligible.
Treactivus™
An in vivo therapeutic solution administered via direct injection into animals, developed for companion animals, animal racing, police (k-9), military canines.
Tatmyctotrans™
- Tatmyctotrans comes in different grades from ruo, clinical and commercial gmp grades.
- Tatmyctotrans is an ancilliary starting raw material that is not present in the final product but is critically important in manufacturing autologous cell therapies.
- Tatmyctotrans is designed to revert anergic/exhausted immune cells to prime them pre-expansion for genetic modification for mrna-T, Car-T, NK cell therapies especially for autologous cell therapies.
- This rescues patient's immune cells that are exhausted due to prior chemotherapy, radiation, checkpoint inhibitors, antibody drug-conjugate's or virus specific cancers such EBV or Hepatitis, enabling effective genetic modifications and expansion.
